Report Summary
Sciensus Pharma Services Limited - Strategic SWOT Insights - A 360° Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence and Operational KPI’s, and Recent Trends is a comprehensive and easily accessible overview of Sciensus Pharma Services Limited 's business operations. It provides a detailed analysis of the company's strategic standing, as well as its position in the industry compared to competitors. The report includes several key features to facilitate decision-making and provide insights into the company's performance.
The report begins with in-depth information about Sciensus Pharma Services Limited including key insights, business segments, key executives, locations, products and services, historical events, corporate strategy, and management discussions. This section provides a solid foundation for understanding the company's key attributes.
Next, the report assesses Sciensus Pharma Services Limited's strategic standing through various analyses. The ESG spotlight evaluates the company's environmental, social, and governance performance, providing insights into its sustainability efforts and ethical practices. The SWOT analysis examines the company's internal strengths and weaknesses, as well as external opportunities and threats. By integrating these strategic analyses, the report offers a comprehensive understanding of Sciensus Pharma Services Limited's overall strategic standing and supports informed decision-making and strategic planning.
Finally, the report includes recent news and deal activities undertaken by Sciensus Pharma Services Limited enhancing awareness of the company's business trends, growth perspectives, and more.
Key Highlights
Sciensus Pharma Services Limited, formerly known as Healthcare at Home, is a leading pharmaceutical supplier and home healthcare provider based in Burton on Trent, UK. Established in 1992 by founder and former chairman Charles Walsh, the company has grown to employ around 1,700 people and serve over 230,000 patients annually across the UK.The company's core services include pharmaceutical supply and distribution, home healthcare services, and specialty pharmacy services.
Sciensus supplies a wide range of pharmaceuticals to patients, healthcare providers, and pharmaceutical companies, working with every NHS trust in the UK to ensure patients have access to the medications they need. The company also specializes in providing in-home care for patients with long-term conditions, rare diseases, and cancer, with a team of healthcare professionals delivering treatments and therapies directly to patients' homes, improving access and convenience.
Additionally, Sciensus offers bespoke services to connect pharmaceutical companies, insurers, and healthcare professionals with patients who require rare, orphan, or hard-to-access medications, including global distribution and patient support programs.However, in 2023, Sciensus faced regulatory issues, including a partial suspension of its license by the MHRA following an incident involving unlicensed chemotherapy treatments. The company was also given a warning by the Parliamentary and Health Service Ombudsman regarding its complaints handling process. Despite these challenges, Sciensus remains a significant player in the UK's healthcare landscape, providing essential services to thousands of patients.
Sciensus Pharma Services Limited in the News:-
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook